Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166176 | 0.80 | PDE4A (0.31) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL22109455 | 0.77 | ALDH1A1 (0.34) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL22002660 | 0.76 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL24702211 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL18685047 | 0.73 | PDE4D (0.31) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL23263802 | 0.73 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL22002404 | 0.73 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12240837 | 0.72 | ALDH1A1 (0.31) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7803266 | 0.70 | PDE4D (0.33) | PDE4D | |
| SCHEMBL22602147 | 0.70 | PDE4D (0.33) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | PDE4D 4805/4885PDE4A 4828/4885PDE4B 4774/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | PDE4D 4795/4885PDE4A 4823/4885PDE4B 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.